共 50 条
- [41] Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Carden, C. P.Frentzas, S.Langham, M.Casamayor, I.Stephens, A. W.Poondru, S.Wheaton, J.Lippman, S. M.Kaye, S. B.Kim, E. S.
- [42] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9072S - 9072SMarshall, JLLewis, NLAmelsberg, ABriscoe, JHwang, JMalik, SCohen, R
- [43] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 143S - 143SLewis, N.Marshall, J.Amelsberg, A.Cohen, R. B.Stopfer, P.Hwang, J.Malik, S.
- [44] Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumorsCANCER RESEARCH, 2023, 83 (07)Choi, Bae JungDevalingam, DevalingamAlistar, AngelaEl-Khoueiry, AnthonyMita, AlainKang, HwankyuChoi, JinhoAhn, HyunjiKim, JeongjunLee, Seung-JooYang, Yeong-InAhn, JiyeJeon, BoramiKim, JaeseungNam, Kiyean
- [45] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBritish Journal of Cancer, 2008, 98 : 80 - 85F A L M EskensC H MomA S T PlantingJ A GietemaA AmelsbergH HuismanL van DoornH BurgerP StopferJ VerweijE G E de Vries
- [46] Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Rihawi, KarimOng, MichaelMichalarea, VasilikiBent, LizBuschke, SusanneBogenrieder, ThomasAnthoney, AlanDe Bono, Johann SebastianTwelves, Chris
- [47] A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursBRITISH JOURNAL OF CANCER, 2008, 98 (01) : 80 - 85Eskens, FalmMom, C. H.Planting, A. S. T.Gietema, J. A.Amelsberg, A.Huisman, H.van Doorn, L.Burger, H.Stopfer, P.Verweij, J.de Vries, Ege
- [48] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2016, 78 : 259 - 269Junning CaoJian ZhangWei PengZhiyu ChenSonghua FanWeiguo SuKe LiJin Li
- [49] A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2, and-3 tyrosine kinases in Chinese patients with advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 259 - 269Cao, JunningZhang, JianPeng, WeiChen, ZhiyuFan, SonghuaSu, WeiguoLi, KeLi, Jin
- [50] Does escalation results from phase Ib/II Norse study of erdafitinib (ERDA) + PD-1 inhibitor JNJ-63723283 (Cetrelimab [CET]) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and selected fibroblast growth factor receptor (FGFR) gene alterationsJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Moreno, VictorLoriot, YohannValderrama, Begona PerezBeato, CarmenVano, Yann-AlexandreFleming, Mark T.Duran, IgnacioSiena, SalvatoreTolbert, Jaszianne A.OHagan, AnneAkapame, SydneyLau, Yvonne Y.Geoffrois, LionnelTagawa, Scott T.Mellado, BegonaSiefker-Radtke, Arlene O.